IL317919A - Preservation of immune response during chemotherapy regimens - Google Patents

Preservation of immune response during chemotherapy regimens

Info

Publication number
IL317919A
IL317919A IL317919A IL31791924A IL317919A IL 317919 A IL317919 A IL 317919A IL 317919 A IL317919 A IL 317919A IL 31791924 A IL31791924 A IL 31791924A IL 317919 A IL317919 A IL 317919A
Authority
IL
Israel
Prior art keywords
inhibitor
cdk4
day
administering
immune checkpoint
Prior art date
Application number
IL317919A
Other languages
English (en)
Hebrew (he)
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62491342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL317919(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of IL317919A publication Critical patent/IL317919A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL317919A 2016-12-05 2017-12-05 Preservation of immune response during chemotherapy regimens IL317919A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662430302P 2016-12-05 2016-12-05
US201762479605P 2017-03-31 2017-03-31
PCT/US2017/064775 WO2018106729A1 (en) 2016-12-05 2017-12-05 Preservation of immune response during chemotherapy regimens

Publications (1)

Publication Number Publication Date
IL317919A true IL317919A (en) 2025-02-01

Family

ID=62491342

Family Applications (4)

Application Number Title Priority Date Filing Date
IL317919A IL317919A (en) 2016-12-05 2017-12-05 Preservation of immune response during chemotherapy regimens
IL303038A IL303038B2 (en) 2016-12-05 2017-12-05 Preservation of immune response during chemotherapy regimens
IL311265A IL311265A (en) 2016-12-05 2017-12-05 Preservation of immune response during chemotherapy regimens
IL266870A IL266870A (en) 2016-12-05 2019-05-26 Preservation of immune response during chemotherapy regimens

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL303038A IL303038B2 (en) 2016-12-05 2017-12-05 Preservation of immune response during chemotherapy regimens
IL311265A IL311265A (en) 2016-12-05 2017-12-05 Preservation of immune response during chemotherapy regimens
IL266870A IL266870A (en) 2016-12-05 2019-05-26 Preservation of immune response during chemotherapy regimens

Country Status (12)

Country Link
US (2) US11529352B2 (enExample)
EP (1) EP3548030A4 (enExample)
JP (4) JP2019536805A (enExample)
KR (4) KR20190092478A (enExample)
CN (3) CN117530948A (enExample)
AU (4) AU2017372856B9 (enExample)
BR (1) BR112019011410A2 (enExample)
CA (1) CA3045465A1 (enExample)
IL (4) IL317919A (enExample)
MX (2) MX2019006523A (enExample)
NZ (2) NZ753631A (enExample)
WO (1) WO2018106729A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105473140B (zh) * 2013-03-15 2018-04-10 G1治疗公司 在化学疗法期间对正常细胞的瞬时保护
EP3138555B1 (en) 2014-04-30 2020-10-28 FUJIFILM Corporation Liposome composition and production method therefor
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
CA3045465A1 (en) 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens
EA201991622A1 (ru) 2017-01-06 2020-01-23 Г1 Терапьютикс, Инк. Комплексная терапия для лечения рака
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
AU2018246024B2 (en) 2017-03-31 2020-08-06 Fujifilm Corporation Liposome composition and pharmaceutical composition
WO2019054865A1 (en) * 2017-09-14 2019-03-21 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T-cell based immunotherapy
WO2019108589A1 (en) * 2017-11-30 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer
PE20210121A1 (es) 2018-01-08 2021-01-19 G1 Therapeutics Inc Regimenes de dosificacion superior de g1t38
AU2019253706A1 (en) * 2018-04-09 2020-11-26 G1 Therapeutics, Inc. Treatment of cancers having driving oncogenic mutations
PL3811931T3 (pl) * 2018-06-20 2024-11-18 Fujifilm Corporation Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
DK3811949T3 (da) * 2018-06-20 2024-10-07 Fujifilm Corp Kombineret medicin omfattende gemcitabin-indkapslet liposomsammensætning og immun-checkpoint-blokade
WO2020058372A1 (en) * 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
WO2020071349A1 (ja) 2018-10-01 2020-04-09 富士フイルム株式会社 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬
JP2022506829A (ja) * 2018-11-09 2022-01-17 ジー１、セラピューティクス、インコーポレイテッド エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン
WO2020219926A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer with cdk inhibitors
JP2022530674A (ja) * 2019-05-03 2022-06-30 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体を用いたがんの処置方法
CN114222577A (zh) * 2019-06-18 2022-03-22 G1治疗公司 增强癌症患者中抗肿瘤免疫的患者选择
EP4231089A3 (en) 2019-11-12 2024-03-13 Pointcloud Inc. Dual path light detection and ranging system
WO2021110122A1 (zh) * 2019-12-05 2021-06-10 基石药业（苏州）有限公司 Cdk4/6抑制剂的组合疗法
EP4652997A2 (en) 2020-05-19 2025-11-26 Pharmacosmos Holding A/s Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
CN116157403B (zh) * 2020-06-15 2025-04-25 海南先声再明医药股份有限公司 曲拉西利的形态及其制造方法
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
TW202231283A (zh) * 2020-10-19 2022-08-16 美商G1治療公司 用於治療轉移性大腸直腸癌之經改良之基於氟尿嘧啶之多藥劑化學治療
EP4255576A4 (en) * 2020-12-07 2024-10-23 The Trustees of Indiana University METHODS FOR SENSITIZING CANCER CELLS TO IMMUNE ATTACK USING ATRACTYLENOLIDE I
CN113788837B (zh) * 2021-08-02 2022-08-26 深圳湾实验室坪山生物医药研发转化中心 Trilaciclib的合成方法
WO2023068220A1 (ja) * 2021-10-18 2023-04-27 株式会社Preferred Networks 予測方法及びバイオマーカー
WO2023164649A2 (en) * 2022-02-25 2023-08-31 Lanier Biotherapeutics, Inc. Anti-alarmin binding molecules and treatment of pneumonitis
CN119816315A (zh) * 2022-09-02 2025-04-11 Rs肿瘤学有限责任公司 硫链丝菌素给药方案
WO2024216208A2 (en) * 2023-04-14 2024-10-17 Concarlo Therapeutics, Inc. Brk peptides and methods of use
WO2024238476A2 (en) * 2023-05-15 2024-11-21 Cedars-Sinai Medical Center Y chromosome gene signature as a target for cancer therapy in combination with immunotherapy
CN117511855B (zh) * 2023-11-09 2024-11-19 南京医科大学 Epha抑制剂在诱导减数分裂中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
KR20080108517A (ko) 2006-04-05 2008-12-15 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
EA200900799A1 (ru) 2006-12-22 2009-12-30 Новартис Аг Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
US8518930B2 (en) 2008-07-29 2013-08-27 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent
NZ591176A (en) 2008-08-22 2012-11-30 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
CA2738909A1 (en) 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
CN102231984A (zh) 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
US20120100100A1 (en) 2009-05-13 2012-04-26 Sharpless Norman E Cyclin dependent kinase inhibitors and methods of use
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
MX379532B (es) 2010-10-25 2025-03-10 G1 Therapeutics Inc Inhibidores de cdk.
PH12013502697A1 (en) 2011-07-01 2014-02-10 Novartis Ag Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
WO2013148748A1 (en) 2012-03-29 2013-10-03 Francis Xavier Tavares Lactam kinase inhibitors
CA2870019C (en) 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
WO2014144596A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
CN105473140B (zh) 2013-03-15 2018-04-10 G1治疗公司 在化学疗法期间对正常细胞的瞬时保护
EP2983670A4 (en) 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
MX2016000750A (es) * 2013-08-02 2016-08-05 Aduro Biotech Holdings Europe B V Combinacion de agonistas de cd27 e inhibicion del punto de control inmunologico para estimulacion del sistema inmunologico.
US20160257688A1 (en) 2013-10-24 2016-09-08 Francis Xavier Tavares Process for Synthesis of Lactams
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
KR20170003692A (ko) 2014-05-15 2017-01-09 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
EP3233123A4 (en) * 2014-12-16 2018-05-09 Bristol-Myers Squibb Company Use of immune checkpoint inhibitors in central nervous systems neoplasms
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
EP3471717A4 (en) 2016-06-20 2020-01-22 Kura Oncology, Inc. Treatment of squamous cell carcinomas with inhibitors of erk
US11865176B2 (en) 2016-11-08 2024-01-09 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
EP3541389A1 (en) 2016-11-16 2019-09-25 Pfizer Inc Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
JP7166252B2 (ja) 2016-11-30 2022-11-07 メディツィーニシェ・ウニヴェルジテート・インスブルック サイクリン依存性キナーゼ阻害剤としての３－アミノ－１，５－ジヒドロピラゾロ［３，４－ｄ］ピリミジン－４－オン
CA3045465A1 (en) 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens
CN111148518A (zh) 2017-03-30 2020-05-12 丹娜法伯癌症研究院 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
WO2019108589A1 (en) 2017-11-30 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer

Also Published As

Publication number Publication date
KR20240024296A (ko) 2024-02-23
WO2018106729A1 (en) 2018-06-14
IL311265A (en) 2024-05-01
NZ753631A (en) 2023-07-28
KR20240023677A (ko) 2024-02-22
AU2023282168B2 (en) 2025-10-09
IL303038B1 (en) 2024-04-01
JP2022116301A (ja) 2022-08-09
AU2023282168A1 (en) 2024-01-04
CN110035759A (zh) 2019-07-19
CN117562905A (zh) 2024-02-20
CA3045465A1 (en) 2018-06-14
CN117530948A (zh) 2024-02-09
KR20190092478A (ko) 2019-08-07
MX2019006523A (es) 2019-10-15
EP3548030A1 (en) 2019-10-09
AU2017372856B2 (en) 2023-12-14
KR20240023676A (ko) 2024-02-22
EP3548030A4 (en) 2020-08-12
AU2017372856A1 (en) 2019-06-06
JP7483791B2 (ja) 2024-05-15
AU2023282170B2 (en) 2025-10-09
IL303038A (en) 2023-07-01
AU2023282170A1 (en) 2024-01-04
MX2023006991A (es) 2023-06-26
RU2019120160A (ru) 2021-01-11
BR112019011410A2 (pt) 2019-10-22
NZ795224A (en) 2025-10-31
US11529352B2 (en) 2022-12-20
AU2017372856B9 (en) 2024-01-04
US20230302001A1 (en) 2023-09-28
JP7710496B2 (ja) 2025-07-18
JP2025148426A (ja) 2025-10-07
IL266870A (en) 2019-08-29
AU2025242155A1 (en) 2025-10-23
IL303038B2 (en) 2024-08-01
US20190321370A1 (en) 2019-10-24
JP2023182577A (ja) 2023-12-26
JP2019536805A (ja) 2019-12-19
RU2019120160A3 (enExample) 2021-04-07

Similar Documents

Publication Publication Date Title
US20230302001A1 (en) Preservation of immune response during chemotherapy regimens
WO2020206035A1 (en) Treatment of cdk4/6 inhibitor resistant neoplastic disorders
EP3738084A1 (en) G1t38 superior dosage regimes
WO2023034336A2 (en) Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility
WO2019222521A1 (en) Cdk inhibitors for the treatment of neoplastic disorders
JP2025525376A (ja) 医学的治療用のサイクリン依存性キナーゼ２阻害剤
RU2779478C2 (ru) Сохранение иммунного ответа во время химиотерапевтических схем
BR122025020789A2 (pt) Uso um inibidor seletivo da cinase dependente da ciclina 4/6 (cdk4/6)
EA043297B1 (ru) Применение ингибитора cdk4/6 в сохранении иммунного ответа во время химиотерапевтических схем
HK40012319A (en) Preservation of immune response during chemotherapy regimens
CN118234496A (zh) 检查点抑制剂耐药或耐药易感性的晚期/转移性癌症的改善治疗
HK40041180A (en) G1t38 superior dosage regimes